Watch now to see how RELISTOR targets mu-opioid receptors
The targeted action of RELISTOR inhibits opioids from binding to mu-receptors in tissues such as the gastrointestinal (GI) tract, decreasing their constipating effects.1
Limitations of Use: Use beyond four months has not been studied in the advanced illness population.
To report SUSPECTED ADVERSE REACTIONS, contact Salix at 1-800-508-0024 or FDA at 1-800-FDA-1088 or www.fda.gov/Safety/MedWatch/
Please click here for full Prescribing Information for RELISTOR tablets and RELISTOR injection.